Lipid accumulation product better predicts metabolic status in lean polycystic ovary syndrome than that by visceral adiposity index

Banu, Hurjahan; Morshed, Md Shahed; Sultana, Tania; Shah, Sukanti; Afrine, Shazia; Hasanat, Muhammad Abul

doi:10.4103/jhrs.jhrs_114_21

Cited by 7 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LAP had an excellent discriminating index for MetS in lean PCOS patients. 19 Additionally, LAP has been recognized as a promising method for evaluating the impact of lifestyle and medication interventions on women with PCOS, aiming to monitor their effectiveness. Lifestyle interventions encompass dietary adjustments and physical activity, which have demonstrated substantial enhancements in LAP and cardiometabolic risk factors prokopakis et al volume 22, issue 3, July -september 2023 among individuals with PCOS.…”

Section: Discussionmentioning

confidence: 99%

“…17,18 Furthermore, recent scientific inquiry has focused on comparing the significance of lipid accumulation product (LAP) to other lipid-related indices, such as the visceral adiposity index (VAI), when assessing metabolic or hormonal imbalances amongst women with PCOS. [19][20][21][22] The visceral adiposity index (VAI) is a mathematical formula that accounts for waist circumference, body mass index, triglycerides, and HDL cholesterol levels -all factors used for the evaluation of visceral fat distribution and possible metabolic hazards. 21,22 In lean PCOS patients, LAP was reported to be a better predictor of metabolic status than VAI, 19 although both indices were correlated with IR and hyperandrogenemia in obese/ overweight women with PCOS.…”

Section: Introductionmentioning

confidence: 99%

“…[19][20][21][22] The visceral adiposity index (VAI) is a mathematical formula that accounts for waist circumference, body mass index, triglycerides, and HDL cholesterol levels -all factors used for the evaluation of visceral fat distribution and possible metabolic hazards. 21,22 In lean PCOS patients, LAP was reported to be a better predictor of metabolic status than VAI, 19 although both indices were correlated with IR and hyperandrogenemia in obese/ overweight women with PCOS. 20 Furthermore, a substantial association was discovered between inflammatory markers and hormonal, metabolic, IR, and obesity indices in first-degree relatives of PCOS patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

Prokopakis,

Pergialiotis,

Sapantzoglou

et al. 2023

HJOG

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) presents one of the most widespread endocrine disorders affecting women of reproductive age, predominantly characterized by hyperandrogenism, anovulation, and polycystic ovaries. Women diagnosed with PCOS also present an increased risk for developing metabolic complications like dyslipidemia, metabolic syndrome (MetS) insulin resistance (IR) and type 2 diabetes mellitus. With effective early detection becoming critical to managing these adverse effects, Lipid Accumulation Product (LAP) has emerged as a reliable marker for detecting excessive lipid accumulation beyond adipose tissue, such as in the liver, often associated with cardiometabolic risk; especially among patients with PCOS. This review examines the link between the application of LAP as a predictor of cardiometabolic risks and its association to PCOS, hence seeking possible implementations in clinical settings towards early diagnosis and improved management for affected individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

Prokopakis,

Pergialiotis,

Sapantzoglou

et al. 2023

HJOG

View full text Add to dashboard Cite

show abstract

“…Human morphologic or obesity measurement indexes can reflect the degree of obesity and have certain screening value for metabolic diseases (6)(7)(8)(9). In addition to body mass index (BMI), there are many other obesity measurement indexes, including traditional indexes such as waist circumference (WC), waist-hip ratio (WHR) and waist-to-height ratio (WHtR), as well as new indexes that have emerged in recent years, such as a body shape index (ABSI), body roundness index (BRI), visceral fat index (VAI) and lipid accumulation product (LAP) (10)(11)(12)(13). In recent years, a small number of studies have explored the correlation between obesity measurement indexes and NAFLD, demonstrating the screening value of the new obesity measurement indexes for NAFLD (14,15).…”

Section: Introductionmentioning

confidence: 99%

Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease

et al. 2023

View full text Add to dashboard Cite

ObjectivesObesity measurement indexes have certain screening value for metabolic diseases. To investigate associations between metabolic associated fatty liver disease (MAFLD) and obesity measurement indexes, including traditional indexes (BMI, WC, WHtR) and new indexes (ABSI, BRI, VAI, LAP), and assess their screening ability.Methods12,658 subjects aged 18-75 at the Health Center of a Class III Grade A Hospital were included, who were divided into MAFLD and non-MAFLD groups. Spearman’s rank correlation was used to study the correlation between MAFLD and obesity measurement indexes. Receiver operating characteristic (ROC) curves were used to calculate the area under the curve (AUC) to evaluate their screening accuracy.ResultsMAFLD had strong correlation with traditional BMI and new index LAP. ROC analysis showed that BMI had the highest AUC (0.89), followed by LAP (0.87). Stratification by BMI, LAP had the highest AUC (0.90) for MAFLD in population without obesity (BMI< 23kg/m2), and its optimal cutoff value was 20.75, with a sensitivity and specificity of 85.9% and 79.0%, respectively.ConclusionsWe proposed a two-step screening strategy for MAFLD, combining BMI and LAP, and defined a high-risk population for MAFLD as follows: 1) BMI ≥ 23 kg/m2; and 2) BMI< 23 kg/m2 and LAP ≥ 20.75.

show abstract

“…Accordingly, VAI has indicated a great predictive performance for the incidence of CVDs 11 . Although numerous studies have evaluated VAI and LAP's ability to predict MetS, DM, and CVDs, few studies have compared these two indexes in predicting the incidence of CVDs and CVD‐related mortality 13–16 . In this study, we compared the predictive performance of VAI and LAP for the incidence of CVDs, all‐cause, and CVD‐related mortality in a population‐based cohort study in central Iran.…”

Section: Introductionmentioning

confidence: 99%

Lipid accumulation product and visceral adiposity index for incidence of cardiovascular diseases and mortality; results from 13 years follow‐up in Isfahan cohort study

Fakhrolmobasheri,

Abhari,

Heidarpour

et al. 2023

Obesity Science & Practice

View full text Add to dashboard Cite

Background/AimsVisceral adiposity index (VAI) and lipid accumulation product (LAP) are novel anthropometric indices that have shown an association with metabolic syndrome; however, limited data are available regarding the predictive performance of these indices for the incidence of cardiovascular diseases (CVD) and mortality.MethodsThis study was performed on the data retrieved from Isfahan Cohort Study (ICS). ICS is an ongoing population‐based cohort study conducted in 3 counties in central Iran. Pearson correlation analysis was performed between LAP, VAI, and metabolic parameters. Cox regression analysis and receiver operative characteristics (ROC) curve analysis were performed in order to evaluate the ability of VAI and LAP for the incidence of CVD, CVD‐associated mortality, and all‐cause mortality. We further compared the predictive performance of VAI and LAP with body mass index (BMI).ResultsLAP and VAI were significantly correlated with all metabolic variables, including blood pressure, fasting blood glucose, and lipid profile components. Univariate regression analysis indicated a significant association between LAP and VAI with CVD incidence. In multivariate analysis, only VAI was significantly associated with CVD incidence. Regarding CVD mortality, only VAI in the multivariate analysis revealed a significant association. Interestingly, Both VAI and LAP were negatively associated with all‐cause mortality. ROC curve analysis indicated the superior performance of LAP and VAI for predicting CVD incidence compared to BMI; however, BMI was better in predicting all‐cause mortality.ConclusionCompared to BMI, LAP and VAI are of better predictive performance for the incidence of CVD. In contrast, BMI was superior to VAI and LAP in the prediction of all‐cause mortality.This article is protected by copyright. All rights reserved.

show abstract

Lipid accumulation product better predicts metabolic status in lean polycystic ovary syndrome than that by visceral adiposity index

Cited by 7 publications

References 32 publications

The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

The Role of Lipid Accumulation Product (LAP) as a Metabolic Indicator in Polycystic Ovary Syndrome (PCOS)

Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease

Lipid accumulation product and visceral adiposity index for incidence of cardiovascular diseases and mortality; results from 13 years follow‐up in Isfahan cohort study

Contact Info

Product

Resources

About